Anti-Human CD3 x CD20 (Epcoritamab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Epcoritamab. Epcoritamab is a bispecific antibody that targets CD3 on T-cells and CD20 on B-cells.

Epcoritamab is a CD20xCD3 Bispecific T cell Engager (BiTE) antibody developed as a cancer immunotherapeutic drug 1 . Simultaneous targeting of CD20 B cell on lymphomas and CD3 on T cells, leads to T cell activation, the release of perforin and granzymes, and ultimately the depletion of malignant B cells through lysis and cell death 1 . This approach is potent in treating B-cell malignancies like non-Hodgkin lymphoma. The distribution of Anti-Human CD3 x CD20 includes blood and lymphatic tissues, enabling effective engagement with T and B-cells, enhancing its therapeutic efficacy^2-4.

Epcoritamab (GEN3013) is a bispecific antibody that targets CD3 on T-cells and CD20 on B- cells, inducing potent T-cell-mediated cytotoxicity against CD20-expressing B-cells. Administered subcutaneously, Epcoritamab has demonstrated significant efficacy in clinical trials for relapsed or refractory B-cell lymphomas. In laboratory settings, Epcoritamab is utilized to study bispecific antibody mechanisms and develop therapeutic strategies for B-cell malignancies^5-7.

CD20 is widely expressed on normal B cells during all stages of development, as well as by most B cell malignancies. CD3 is a T cell surface glycoprotein.

CD3ε: TCR
CD20: Src family tyrosine kinases, MHC class I, II, CD53, CD81, CD82

CD3ε: P07766
CD20: P11836

1 Kang C. Drugs. 82(11):1229-1234. 2022.
2. Xiong D, Xu Y, Liu H, et al. Cancer Lett. 2002;177(1):29-39.
3. Chen Q, Yuan S, Sun H, Peng L. Hum Immunol. 2019;80(3):191-194.
4. Liu Y, Ao K, Bao F, et al. Vaccines (Basel). 2022;10(8):1335.
5. Izutsu K, Kumode T, Yuda J, et al. Cancer Sci. 2023;114(12):4643-4653.
6. Thieblemont C, Phillips T, Ghesquieres H, et al. J Clin Oncol. 2023;41(12):2238-2247.
7. Hutchings M, Mous R, Clausen MR, et al. Lancet. 2021;398(10306):1157-1169.